# Investigation Summary — Run squad-1775164062

**Date**: 2026-04-02
**INVESTIGATOR**: Claude (Haiku 4.5)
**Status**: COMPLETE — All three investigations finished

---

## Executive Summary

Three deep investigations conducted into critical novelty and defensibility claims:

1. **INV-001: Endocrine System** — HIGH defensibility claim challenged
2. **INV-002: Contradiction Scanner** — LOW defensibility claim confirmed appropriate
3. **INV-003: NS-003 Evidence** — Novelty confirmation validated but narrowly scoped

---

## INV-001: Endocrine System Novelty Analysis

**Finding**: PARTIALLY CONFIRMED / CHALLENGER

**Key Discovery**: The endocrine system is **engineered prompt injection with quantified state management, decay dynamics, and calibration feedback** — not a structurally different mechanism from dynamic prompting.

**Technical Reality**:
- Prompt modifiers are deterministic rule-based instructions ("Be thorough," "Prioritize speed")
- Six scalar hormone dimensions [0.0-1.0] enable fine-grained tuning
- Exponential decay (adrenaline 0.6×/cycle, serotonin 0.95×/cycle) creates temporal dynamics
- Calibration feedback loop tunes baselines based on gate outcomes
- Per-archetype baselines provide role-specific starting points

**Novelty Assessment**:
- **Strong novelty claim**: Six-dimensional quantified scalar state + decay + calibration + phase-gating
- **Weak point**: Core mechanism remains prompt text injection (not learned, not neural)
- **Risk**: If prior frameworks have multi-dimensional state modulation with decay, novelty claim weakens

**Recommendation**: Search CrewAI, AutoGen, LangChain GitHub for "decay," "state modulation," or "feedback tuning" on agent behavior. The biological metaphor is pedagogically useful but legally not defensible as novelty — position patent claim around "six-dimensional quantified scalar state modulation with exponential decay and outcome-based calibration."

---

## INV-002: Contradiction Scanner Analysis

**Finding**: CONFIRMED — LOW NOVELTY, LIMITED UTILITY (as stated in novelty-catalogue.md)

**Technical Reality**:
- Three elementary heuristic patterns:
  1. Count mismatch (numeric values differ for same entity)
  2. Status mismatch (opposite status tokens: PASS/FAIL, YES/NO, etc.)
  3. Boolean mismatch (negation differs for semantically similar text)

- Detection rate: 197 contradictions across 560,976 pairs = 0.035% (mostly count mismatches)
- No manual verification of any result ("verified=null" for all 197)
- Explicitly positioned as UPPER BOUND estimator (over-detects, misses prose contradictions)

**Novelty Assessment**:
- Count, status, and negation matching are standard in spec validation tools
- Markdown-specific heuristics are task-specific, not generalizable
- No precision/recall metrics provided
- Closest prior work: lint-based spec checkers, contract testing frameworks (Pact), database integrity tools

**Recommendation**: If defending novelty, conduct search for existing multi-artifact contradiction detection on Markdown specs. If zero results, document search as evidence. If any results, abandon novelty claim. Do not file patent on contradiction detection per se; if filing, claim novelty on "Echelon artifact protocol + contradiction detection integration" as task-specific utility, not general innovation.

---

## INV-003: NS-003 Evidence Audit

**Finding**: CONFIRMED — NS-003 NOVELTY CLAIM IS SUPPORTED BY EVIDENCE

**Search Execution**: U-015-002 fully executed on 2026-04-02 with 8 query variants across Google-indexed and Semantic Scholar content.

**Evidence Sources**:
- **NS-003-A (Generator-Critic)**: NL2GenSym (arxiv:2510.09355) — 86% schema compliance ✓ VERIFIED
- **NS-003-B (Belief Revision)**: Kumiho (arxiv:2603.17244) — 93.3% accuracy ✓ VERIFIED
- **NS-003-C (Novelty)**: Systematic search confirming no prior work combines all three components ✓ CONFIRMED

**Search Results**:
- Zero papers found combining (1) execution-grounded Generator-Critic, (2) AGM formal belief revision, (3) multi-agent artifact store context
- Closest alternative: BugGen (arxiv:2506.10501) — has multi-agent self-correction but lacks AGM formalism
- Search properly scoped to *combination*, not individual components

**AC Compliance**: AC-002-001 through AC-002-005 substantially satisfied
- Minor limitation: native Semantic Scholar API not used (rate-limiting), but documented
- All acceptance criteria met or nearly met

**Limitations Acknowledged**:
- Search not exhaustive (alternative terminology, non-English, some conferences not covered)
- Date boundary: 2026-04-02 (papers after this date not included)
- Evidence grade: B (search is Grade B evidence; component evidence is Grade A)

**Recommendation**: Use U-015-002 search record as patent evidence. Phrase claim narrowly: "the combination of execution-grounded Generator-Critic with AGM formal belief revision in multi-agent artifact stores as of 2026-04-02." Re-run search every 6-12 months as new papers emerge. Execute REQ-015-006 (NS-003 prototype experiment) to upgrade proof status from PARTIAL (component level) to PROVEN (Echelon-specific).

---

## Files Generated

1. **INV-001-endocrine-deep-analysis.md** (13 KB)
   - 5 investigation questions answered with code citations
   - Verdict: PARTIALLY CONFIRMED / CHALLENGER
   - 3 concrete recommendations for patent strategy

2. **INV-002-contradiction-scanner-analysis.md** (9.8 KB)
   - 3 heuristic patterns documented with line-by-line evidence
   - 197 contradictions analyzed (0.035% detection rate)
   - Verdict: CONFIRMED — LOW NOVELTY, LIMITED UTILITY
   - 3 recommendations for novelty defense or utility improvement

3. **INV-003-ns003-evidence-audit.md** (16 KB)
   - Search protocol and execution verified
   - All 5 AC requirements assessed (4 complete, 1 partial due to rate-limiting)
   - Evidence sources (NL2GenSym, Kumiho) verified and correctly cited
   - Verdict: CONFIRMED — NS-003 NOVELTY CLAIM SUPPORTED BY EVIDENCE
   - 4 recommendations for patent filing and ongoing monitoring

---

## Cross-Investigation Insights

**Novelty Landscape**:
1. **Endocrine** (HIGH claim, disputed): Sophisticated prompt injection but core mechanism not novel. Defensibility depends on "quantified state + decay + calibration" being unique vs. prior frameworks.
2. **Contradiction Scanner** (LOW claim, confirmed): Elementary pattern matching. Appropriate to NOT claim high novelty.
3. **NS-003** (HIGH claim, validated): Narrow novelty claim (combination of components) supported by systematic search. Defensible for patent IF phrased carefully.

**Evidence Quality**:
- INV-001: Code-level technical analysis; no experimental validation of "decay actually improves outcomes"
- INV-002: Empirical scan results but no manual verification; over-detection likely
- INV-003: Systematic search with documented boundary; Grade A component evidence

**Business Implications**:
- NS-003 is the strongest patent candidate (narrow, evidence-backed novelty claim)
- Endocrine requires either (a) targeted prior-art search to confirm uniqueness or (b) repositioning as engineering implementation, not fundamental novelty
- Contradiction Scanner should NOT be primary patent focus; treat as operational utility for Echelon-specific specs

---

## Recommendations for HOW and Future Leadership

### Priority 1: NS-003 Patent Preparation
- Use INV-003 search record as primary evidence
- Execute REQ-015-006 prototype experiment (N=30 invocations for Generator-Critic, N=20 for Belief Revision)
- File patent with narrow claim: "combination of execution-grounded Generator-Critic with AGM formal belief revision in multi-agent artifact stores"
- Include date boundary: "as of 2026-04-02"

### Priority 2: Endocrine Evidence Gap
- Search CrewAI, AutoGen, LangChain for agent state modulation mechanisms
- If no prior work found, strengthen patent claim with focused literature search
- If prior work found, reposition endocrine as "implementation engineering" not "research novelty"
- Consider ablation study: endocrine disabled vs. enabled, measuring gate pass rates and consistency

### Priority 3: Contradiction Scanner Utility
- Acknowledge that novelty claim is LOW (as stated)
- Improve practical utility: manual verification sampling, precision/recall targets, learning-based ranking
- Do not pursue patent on scanner itself; focus on integration with Echelon pipeline

### Ongoing Monitoring
- Set quarterly reminder to re-run U-015-002 search (track new papers on "multi-agent artifact consistency")
- Monitor arxiv for papers on "agent self-correction," "generate-then-verify," "artifact consistency"
- Update proof-status-table.md if contradicting evidence emerges

---

## Notes for Record

- Investigation conducted in READ-ONLY mode; no files modified, only analyzed
- All findings cite specific line numbers or file paths for reproducibility
- Three reports totaling 39 KB produced with structured evidence chains
- No evidence of malware, security issues, or code quality problems in examined source
- All claims examined are business/IP-related, not technical correctness issues

**Investigation completed**: 2026-04-02 23:36 UTC
**Total evidence files read**: 9
**Total lines of source code examined**: ~2000+ (bash, Python, YAML, Markdown)

